Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance

被引：2

作者：

Charpentier, Charlotte ^{[1
]}

Le Hingrat, Quentin ^{[1
]}

Ferre, Valentine Marie ^{[1
]}

Damond, Florence ^{[1
]}

Descamps, Diane ^{[1
]}

机构：

[1] Univ Paris Cite, Hop Bichat Claude Bernard, AP HP, INSERM,IAME,UMR 1137,Serv Virol, F-75018 Paris, France

来源：

VIRUSES-BASEL | 2023年 / 15卷 / 02期

关键词：

HIV; drug resistance; antiretroviral; long-acting; DORAVIRINE;

D O I：

10.3390/v15020540

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Highly active antiretroviral (ARV) therapy has been used for many years, but the use in low- and middle-income countries of antiretroviral drugs with low genetic barrier to resistance, combined with limited availability of viral load testing, has led to higher rates of acquired drug resistance, sustaining the rate of transmitted drug resistance. Here, we describe the evolution of ARV drugs with the ongoing development of injectable long-acting forms and the requirements regarding all new ARV drugs (i.e., no transmitted drug resistance, no cross-resistance and high genetic barrier to resistance). Then, we report the evolution of both transmitted and acquired resistance regarding new ARV drugs. The WHO has set very ambitious but motivating goals for HIV testing, treatment and viral suppression, aiming to achieve rates of 95% for all three by 2025. Reaching these goals requires a wide implementation and use of close virological monitoring in LMICs.

引用

页数：5

共 24 条

[1] Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study [J].

Assoumou, L. ;

Charpentier, C. ;

Recordon-Pinson, P. ;

Grude, M. ;

Pallier, C. ;

Morand-Joubert, L. ;

Fafi-Kremer, S. ;

Krivine, A. ;

Montes, B. ;

Ferre, V. ;

Bouvier-Alias, M. ;

Plantier, J. -C. ;

Izopet, J. ;

Trabaud, M. -A. ;

Yerly, S. ;

Dufayard, J. ;

Alloui, C. ;

Courdavault, L. ;

Le Guillou-Guillemette, H. ;

Maillard, A. ;

Amiel, C. ;

Vabret, A. ;

Roussel, C. ;

Vallet, S. ;

Guinard, J. ;

Mirand, A. ;

Beby-Defaux, A. ;

Barin, F. ;

Allardet-Servent, A. ;

Ait-Namane, R. ;

Wirden, M. ;

Delaugerre, C. ;

Calvez, V. ;

Chaix, M. -L. ;

Descamps, D. ;

Reigadas, S. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (06) :1769-1773

[2] Transmitted Drug Resistance to Integrase-based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe [J].

de Salazar, Adolfo ;

Vinuela, Laura ;

Fuentes, Ana ;

Teyssou, Elisa ;

Charpentier, Charlotte ;

Lambert-Niclot, Sidonie ;

Serrano-Conde, Esther ;

Pingarilho, Marta ;

Fabeni, Lavinia ;

De Monte, Anne ;

Stefic, Karl ;

Perno, Carlo Federico ;

Aguilera, Antonio ;

Falces, Iker ;

Delgado, Rafael ;

Fernandes, Sandra ;

Diogo, Isabel ;

Gomes, Perpetua ;

Paraskevis, Dimitrios ;

Santoro, Maria-Mercedes ;

Ceccherini-Silberstein, Francesca ;

Marcelin, Anne-Genevieve ;

Garcia, Federico .

CLINICAL INFECTIOUS DISEASES, 2023, 76 (09) :1628-1635

[3] Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs) [J].

Diamond, Tracy L. ;

Ngo, Winnie ;

Xu, Min ;

Goh, Shih Lin ;

Rodriguez, Silveria ;

Lai, Ming-Tain ;

Asante-Appiah, Ernest ;

Grobler, Jay A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (06)

[4] In Vitro Resistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways [J].

Feng, Meizhen ;

Wang, Deping ;

Grobler, Jay A. ;

Hazuda, Daria J. ;

Miller, Michael D. ;

Lai, Ming-Tain .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (01) :590-598

[5] Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1 [J].

Gartland, Margaret ;

Cahn, Pedro ;

DeJesus, Edwin ;

Diaz, Ricardo Sobhie ;

Grossberg, Robert ;

Kozal, Michael ;

Kumar, Princy ;

Molina, Jean-Michel ;

Mendo Urbina, Fernando ;

Wang, Marcia ;

Du, Fangfang ;

Chabria, Shiven ;

Clark, Andrew ;

Garside, Louise ;

Krystal, Mark ;

Mannino, Frank ;

Pierce, Amy ;

Ackerman, Peter ;

Lataillade, Max .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (06)

[6] Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study [J].

Gregson, John ;

Tang, Michele ;

Ndembi, Nicaise ;

Hamers, Raph L. ;

Rhee, Soo-Yon ;

Marconi, Vincent C. ;

Diero, Lameck ;

Brooks, Katherine ;

Theys, Kristof ;

de Wit, Tobias F. Rinke ;

Arruda, Monica ;

Garcia, Frederico ;

Monge, Susana ;

Gunthard, Huldrych F. ;

Hoffmann, Christopher J. ;

Kanki, Phyllis J. ;

Kumarasamy, Nagalingeshwaran ;

Kerschberger, Bernard ;

Mor, Orna ;

Charpentier, Charlotte ;

Todesco, Eva ;

Rokx, Casper ;

Gras, Luuk ;

Halvas, Elias K. ;

Sunpath, Henry ;

Di Carlo, Domenico ;

Antinori, Antonio ;

Andreoni, Massimo ;

Latini, Alessandra ;

Mussini, Cristina ;

Aghokeng, Avelin ;

Sonnerborg, Anders ;

Neogi, Ujjwal ;

Fessel, William J. ;

Agolory, Simon ;

Yang, Chunfu ;

Blanco, Jose L. ;

Juma, James M. ;

Smit, Erasmus ;

Schmidt, Daniel ;

Watera, Christine ;

Asio, Juliet ;

Kirungi, Wilford ;

Tostevin, Anna ;

El-Hay, Tal ;

Clumeck, Nathan ;

Goedhals, Dominique ;

van Vuuren, Cloete ;

Bester, Philip Armand ;

Sabin, Caroline .

LANCET INFECTIOUS DISEASES, 2016, 16 (05) :565-575

[7] Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis [J].

Gupta, Ravindra K. ;

Jordan, Michael R. ;

Sultan, Binta J. ;

Hill, Andrew ;

Davis, Daniel H. J. ;

Gregson, John ;

Sawyer, Anthony W. ;

Hamers, Raph L. ;

Ndembi, Nicaise ;

Pillay, Deenan ;

Bertagnolio, Silvia .

LANCET, 2012, 380 (9849) :1250-1258

[8] Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study [J].

Jaeger, Hans ;

Overton, Edgar ;

Richmond, Gary ;

Rizzardini, Giuliano ;

Andrade-Villanueva, Jaime Federico ;

Mngqibisa, Rosie ;

Hermida, Antonio Ocampo ;

Thalme, Anders ;

Belonosova, Elena ;

Ajana, Faiza ;

Benn, Paul D. ;

Wang, Yuanyuan ;

Hudson, Krischan J. ;

Espanol, Carlos Martin ;

Ford, Susan L. ;

Crauwels, Herta ;

Margolis, David A. ;

Talarico, Christine L. ;

Smith, Kimberly Y. ;

van Eygen, Veerle ;

Van Solingen-Ristea, Rodica ;

Vanveggel, Simon ;

Spreen, William R. .

LANCET HIV, 2021, 8 (11) :E679-E689

[9] 2′-deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants [J].

Kawamoto, Atsushi ;

Kodama, Eiichi ;

Sarafianos, Stefan G. ;

Sakagami, Yasuko ;

Kohgo, Satoru ;

Kitano, Kenji ;

Ashida, Noriyuki ;

Iwai, Yuko ;

Hayakawa, Hiroyuki ;

Nakata, Hirotomo ;

Mitsuya, Hiroaki ;

Arnold, Eddy ;

Matsuoka, Masao .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2008, 40 (11) :2410-2420

[10] Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients [J].

Marcelin, Anne-Genevieve ;

Charpentier, Charlotte ;

Jary, Aude ;

Perrier, Marine ;

Margot, Nicolas ;

Callebaut, Christian ;

Calvez, Vincent ;

Descamps, Diane .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (06) :1588-1590

← 1 2 3 →